2nd Edition of Cosmetology Aging and Rejuvenation World Conference 2026

Abstract

Alopecia Areata (AA) is one of the most common autoimmune diseases that causes non-scarring, patchy hair loss. The most severe type of Alopecia areata is alopecia totalis (AT). Affected patients have association of psychological disease and shown decreased quality of life. Despite the fact that there are several treatment options available for AA, most of them do not provide satisfactory results when it comes to AT.

 Despite the fact that there are a number of treatment options available for AA, the most of them do not provide satisfying results when it comes to AT. The disease is distinguished by the invasion of hair bulbs by activated T lymphocytes cells. The pathophysiology of alopecia areata reveals CD4 cell depletion. AA has hereditary correlations with genes of major his to compatibility complex (MHC). In recent years, multiple series, case reports, and small open-label trials have demonstrated the effectiveness of oral Janus kinase (JAK) inhibitors as a therapy for AT. One of the commonly used JAK inhibitor for the treatment of psoriatic and rheumatoid arthritis is tofacitinib. Here, we present a 21-year-old male patient who had effective treatment for Alopecia totalis with tofacitinib. The patient lost all of his but regained after six months of therapy, and there was no sign of a recurrence. The patient responded favourably to the therapy; by the fourth week, hair had begun to grow, and by the sixth month, complete regrowth had been achieved. There were no significant negative effects reported. For AT, tofacitinib may be a well-tolerated and effective therapy option; however, more research is required to determine its long-term effectiveness.